Furthermore, to achieve specific targeting of selected tumor or stromal cells, bi-functional TRAIL-R1 or -R2 agonistic antibodies or TRAIL fusion proteins have been developed containing a cell-specific binding moiety in addition to a TRAIL-R binding part. The gene discussed is TNFRSF10A; the disease is neoplasm.